CONDOR Phase 3: Brolucizumab vs PRP in PDR
Key Questions
What were the key results of the CONDOR Phase 3 trial comparing brolucizumab to PRP for proliferative diabetic retinopathy?
In the CONDOR trial, brolucizumab q12w showed a +0.2 letter BCVA change versus -4.2 letters with PRP at week 54. It achieved 64% PDR-free patients compared to 22% with PRP and 33% fewer vision threats. A 5% rate of intraocular inflammation (IOI) was observed.
How did brolucizumab compare to panretinal laser photocoagulation in vision outcomes for diabetic retinopathy?
The CONDOR Phase 3 trial demonstrated that brolucizumab outperformed PRP in treating proliferative diabetic retinopathy. Patients on brolucizumab maintained better best-corrected visual acuity and had substantially higher rates of PDR resolution. These results align with the related finding that brolucizumab bests laser in diabetic retinopathy vision outcomes.
What updates or reinforcements are expected for the CONDOR trial findings in diabetic retinopathy treatment?
DRCR 2026 updates are noted to reinforce the shifts toward anti-VEGF approaches like brolucizumab over traditional PRP. The trial's efficacy data, including vision preservation and PDR control, support evolving standards in PDR management. Safety monitoring for IOI remains relevant in ongoing evaluations.
Ph3 JAMA: brolucizumab q12w +0.2L vs -4.2L BCVA vs PRP wk54, 64% PDR-free vs 22%, 33% fewer threats, 5% IOI. DRCR 2026 updates reinforce shifts.